Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

MorphoSys

Biotech & Life Sciences · Planegg, Germany · Founded 1992 · IPO 2018 Unicorn

Biotechnology company focused on the research and development of fully human antibodies

Valuation
$2.72B
Market cap · 2026
Revenue
$262M
Latest reported FY
Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

9 investors on MorphoSys's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage
Atlas Venture
Series A 4 investors entered at this stage
Genentech
Third Rock Ventures
Venrock
The Column Group
Series B+ 4 investors entered at this stage
Max Planck Institute for Biological Intelligence
Max Planck Innovation
Max Planck Institute of Biochemistry
Max Planck Society

Global footprint

Where MorphoSys has talent and traffic

Workforce by country
8 countries with
team presence
🇩🇪 Germany79.2%
🇺🇸 United States16.8%
🇨🇭 Switzerland1.8%
🇦🇷 Argentina0.6%
🇮🇳 India0.6%
Top 5 of 8 shown
Web traffic by country
450 monthly visits
across markets
🇺🇸 United States66.7%
🇬🇪 Georgia22.2%
Top 2 markets shown

Patent intelligence

$322M patent portfolio · 149 active families

Estimated portfolio value
$322M
11.8% of market cap · 6.3× smaller than top peer Ablynx ($2B)
149 active patent families
Where MorphoSys innovates Molecular biologyOncologyBiochemistryBioinformaticsPharmaceutical medicine

Where MorphoSys concentrates vs peers

Each axis is a top-10 topic across MorphoSys and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

MorphoSys's 4 investments and acquisitions.

Every disclosed deal where MorphoSys appeared as a backer or acquirer, 2010–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across MorphoSys's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where MorphoSys deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        MorphoSys's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        What the market is saying about MorphoSys

        An AI-synthesized read of the highest-engagement posts about MorphoSys on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See MorphoSys on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles